^
    1d
    Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
    Enrollment open
    17d
    B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov)
    P1, N=14, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    1m
    Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Anusha Kalbasi | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV
    2ms
    CD123 Redirected T Cells for AML in Pediatric Subjects (clinicaltrials.gov)
    P1, N=12, Terminated, University of Pennsylvania | N=18 --> 12 | Trial completion date: Jan 2036 --> May 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2036 --> May 2025; Administrative reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • CART123
    2ms
    CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) (clinicaltrials.gov)
    P1, N=108, Recruiting, St. Jude Children's Research Hospital | N=56 --> 108
    Enrollment change
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • CD123-CAR T cell therapy
    2ms
    CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children (clinicaltrials.gov)
    P1, N=18, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Feb 2026 | Trial primary completion date: Aug 2025 --> Feb 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    cyclophosphamide • fludarabine IV
    2ms
    Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, University of Pennsylvania
    New P1 trial
    2ms
    CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial
    2ms
    B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov)
    P1, N=14, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1 trial • First-in-human
    3ms
    NCI-2014-01147: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    cyclophosphamide • fludarabine IV • CD123R(EQ)28zeta/EGFRt+ T cells
    3ms
    Combination CAR-T Cell Therapy Targeting Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Unknown status --> Recruiting | Trial completion date: Dec 2021 --> Dec 2029 | Trial primary completion date: Jul 2019 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD22 (CD22 Molecule) • CD70 (CD70 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    TNFRSF8 expression
    3ms
    Intervention of Bladder Cancer by CAR-T (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Shenzhen Geno-Immune Medical Institute | Unknown status --> Recruiting | Trial completion date: Dec 2020 --> Dec 2029 | Trial primary completion date: Dec 2019 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    4SCAR-T